Argent BioPharma - About the company
Argent BioPharma is a public company based in London (United Kingdom), founded in 2023. It operates as a Drug discovery company focused on the central nervous system and immunology. The company has 3661 active competitors, including 1171 funded and 883 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and BeiGene.
Company Details
Drug discovery company focused on the central nervous system and immunology. The company is pioneering integration of Nanotechnology and Multidisciplinary research methods to develop multi-targeted drug therapies in the areas of immunology and neurology.
- Website
- argentbiopharma.com
- Social
- Email ID
- *****@argentbiopharma.com
Key Metrics
Founded Year
2023
Location
London, United Kingdom
Stage
Public
Ranked
713th among 3661 active competitors
Employee Count
15 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Argent BioPharma's IPO details
Argent BioPharma got listed on Dec 21, 2006.
Click here to take a look at Argent BioPharma's IPO in detail
Sign up to download Argent BioPharma's company profile
Argent BioPharma's funding and investors
Argent BioPharma has not raised any funding rounds yet.
Argent BioPharma's founders and board of directors
Founder? Claim ProfileArgent BioPharma's employee count trend
Argent BioPharma has 15 employees as of Sep 26. Here is Argent BioPharma's employee count trend over the years:
Uncover Argent BioPharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Argent BioPharma's Competitors and alternates
Top competitors of Argent BioPharma include Jazz Pharmaceuticals, Biogen and BeiGene. Here is the list of Top 10 competitors of Argent BioPharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 77/100 | |
4th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 76/100 | ||
5th | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 73/100 | |
6th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
7th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
9th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
10th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
713th |  Argent BioPharma 2023, London (United Kingdom), Public | Drug discovery company focused on the central nervous system and immunology | - | - | 48/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Argent BioPharma's competitors? Click here to see the top ones
Argent BioPharma's Investments and acquisitions
Argent BioPharma has made no investments or acquisitions yet.
Reports related to Argent BioPharma
Here is the latest report on Argent BioPharma's sector:
News related to Argent BioPharma
Filter this listMedia has covered Argent BioPharma for a total of 9 events in the last 1 year, 2 of them have been about company updates and 2 about partnerships.
•
Argent BioPharma (ASX:RGT) Expands CannEpil® Development Strategy with U.S. Veterinary ProgrammeKalkine•Aug 11, 2026•Argent BioPharma
•
Splash Beverage Group acquires global rights to CannEpil, secures financing and 20-year licenseSeeking Alpha•Jul 07, 2026•Splash Beverage Group, Argent BioPharma
•
Argent Biopharma's Revenues Drop, Outgoings Rise Ahead of AusCann DealBusiness of Cannabis•Feb 18, 2026•Argent BioPharma, AusCann
•
Argent Biopharma Secures A$11 Million Funding Through Convertible NotesTipRanks•Dec 03, 2025•CM Capital Partners, Argent BioPharma
•
Argent BioPharma Secures A$11M Financing for AusCann Group Asset AcquisitionTipRanks•Nov 17, 2025•Argent BioPharma, AusCann, C.M. Capital
•
Argent BioPharma Grows Through M&A; to Acquire AC8 Assets; Projected Merged Company Value of $100MPR Newswire•Aug 28, 2025•Argent BioPharma, AusCann
•
Argent BioPharma to Acquire AusCann's Assets and IP in $15M DealCannabiz•Aug 19, 2025•Argent BioPharma, CannPal, AusCann
•
Argent BioPharma Expands Pipeline with Promising Drug CimetrA®PR Newswire•Mar 17, 2025•Argent BioPharma
•
Argent BioPharma Ltd. Updates on SINTEF Collaboration for Chronic Wound ManagementBenzinga•Feb 13, 2025•Argent BioPharma
•
Edison Group values Argent BioPharma's epilepsy drug at $327M, despite its $12M market cap.PR Newswire•Feb 06, 2025•Argent BioPharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Argent BioPharma
Explore our recently published companies
- Kleona - Unfunded company
- Schooluniformsdirect - Unfunded company
- Lokta - Germany based, Unfunded company
- Malinos - Germany based, Unfunded company
- Supermarket24h - Unfunded company
- Roessler-Trauerpapier - Germany based, Unfunded company
